The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19
Open accessAbstract
Drug repurposing provides a rapid approach to meet the urgent need for therapeutics to address COVID-19. To identify therapeutic targets relevant to COVID-19, we conducted Mendelian randomization analyses, deriving genetic instruments based on transcriptomic and proteomic data for 1,263 actionable proteins that are targeted by approved drugs or in clinical phase of drug development. Using summary statistics from the Host Genetics Initiative and the Million Veteran Program, we studied 7,554 patients hospitalized with COVID-19 and >1 million controls. We found significant Mendelian randomization results for three proteins (ACE2, P = 1.6 × 10−6; IFNAR2, P = 9.8 × 10−11 and IL-10RB, P = 2.3 × 10−14) using cis-expression quantitative trait loci genetic instruments that also had strong evidence for colocalization with COVID-19 hospitalization. To disentangle the shared expression quantitative trait loci signal for IL10RB and IFNAR2, we conducted phenome-wide association scans and pathway enrichment analysis, which suggested that IFNAR2 is more likely to play a role in COVID-19 hospitalization. Our findings prioritize trials of drugs targeting IFNAR2 and ACE2 for early management of COVID-19. Large-scale Mendelian randomization and colocalization analyses using gene expression and soluble protein data for 1,263 actionable druggable genes, which encode protein targets for approved drugs or drugs in clinical development, identify IFNAR2 and ACE2 as the most promising therapeutic targets for early management of COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China
Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., Chang, J., Hong, C., Zhou, Y., Wang, D., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1127 · Cited by 7,166
METAL: fast and efficient meta-analysis of genomewide association scans
Willer, C. J., Li, Y., & Abecasis, G. R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq340 · Cited by 5,205
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science · doi:10.1126/science.abd4585 · Cited by 2,662
Genomic atlas of the human plasma proteome
Sun, B. B., Maranville, J. C., Peters, J. E., Stacey, D., Staley, J. R., Blackshaw, J., Burgess, S., Jiang, T., Paige, E., Surendran, P., et al. (2018) · Nature · doi:10.1038/s41586-018-0175-2 · Cited by 2,268 · cited 5×
“(Boulder, 496 Colorado, US) SomaScan(53,54) platform: (1) Sun et al.(15), which reported results for 2,994 proteins 497 in 3,301 INTERVAL participants and (2) Pietzner et al.”
BackgroundMethodInfluentialSelf-citationInborn errors of type I IFN immunity in patients with life-threatening COVID-19
Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I. K. D., Hodeib, S., Korol, C., et al. (2020) · Science · doi:10.1126/science.abd4570 · Cited by 2,229
Cited by
Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants
Sun, B. B., Chiou, J., Traylor, M., Benner, C., Hsu, Y.-H., Richardson, T. G., Surendran, P., Mahajan, A., Robins, C., Vasquez-Grinnell, S. G., et al. (2022) · doi:10.1101/2022.06.17.496443 · Cited by 1,833
Self-citationPlasma proteomic associations with genetics and health in the UK Biobank
Sun, B. B., Chiou, J., Traylor, M., Benner, C., Hsu, Y.-H., Richardson, T. G., Surendran, P., Mahajan, A., Robins, C., Vasquez-Grinnell, S. G., et al. (2023) · Nature · doi:10.1038/s41586-023-06592-6 · Cited by 1,880
Self-citationZdrazil, B., Felix, E., Hunter, F., Manners, E. J., Blackshaw, J., Corbett, S., de Veij, M., Ioannidis, H., Lopez, D. M., Mosquera, J. F., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad1004 · Cited by 1,413
Self-citationFXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., Wang, L., Griffiths, C., Brown, M. L., Scott, W. E., et al. (2023) · Nature · doi:10.1038/s41586-022-05594-0 · Cited by 293
Qiu, Y., Hou, Y., Gohel, D., Zhou, Y., Xu, J., Bykova, M., Yang, Y., Leverenz, J. B., Pieper, A. A., Nussinov, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114128 · Cited by 40
Metadata
- Authors
- Gaziano, L., Giambartolomei, C., Pereira, A. C., Gaulton, A., Posner, D. C., Swanson, S. A., Ho, Y.-L., Iyengar, S. K., Kosik, N. M., Vujkovic, M., Gagnon, D. R., Bento, A. P., Barrio-Hernandez, I., Rönnblom, L., Hagberg, N., Lundtoft, C., Langenberg, C., Pietzner, M., Valentine, D., Gustincich, S., Tartaglia, G. G., Allara, E., Surendran, P., Burgess, S., Zhao, J. H., Peters, J. E., Prins, B. P., Angelantonio, E. D., Devineni, P., Shi, Y., Lynch, K. E., DuVall, S. L., Garcon, H., Thomann, L. O., Zhou, J. J., Gorman, B. R., Huffman, J. E., O’Donnell, C. J., Tsao, P. S., Beckham, J. C., Pyarajan, S., Muralidhar, S., Huang, G. D., Ramoni, R., Beltrao, P., Danesh, J., Hung, A. M., Chang, K.-M., Sun, Y. V., Joseph, J., Leach, A. R., Edwards, T. L., Cho, K., Gaziano, J. M., Butterworth, A. S., Casas, J. P., & Initiative, V. M. V. P. C.-1. S.
- Venue
- Nature Medicine
- Published
- 2021-04
- Volume
- 27
- Issue
- 4
- Pages
- 668-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W3155185892
- Cited by
- 235
- References
- 25
- FWCI
- 24.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. https://app.cochat.ai/papers/10.1038/s41591-021-01310-z
- The paper
- Gaziano, L., Giambartolomei, C., Pereira, A. C., Gaulton, A., Posner, D. C., Swanson, S. A., Ho, Y.-L., Iyengar, S. K., Kosik, N. M., Vujkovic, M., Gagnon, D. R., Bento, A. P., Barrio-Hernandez, I., Rönnblom, L., Hagberg, N., Lundtoft, C., Langenberg, C., Pietzner, M., Valentine, D., . . . Initiative, V. M. V. P. C.-1. S. (2021). Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. Nature Medicine. https://doi.org/10.1038/s41591-021-01310-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.